#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide...

CHICAGO, IL USA (UroToday.com) - Full Title: #ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer who have bone metastases

Presented by Daniel Petrylak, MD,1 Julie A. Rosenberg, MD,2 Vittorio Luigi Garosi, MD, PhD,3 Jonathan Siegel,2 and Jonathan Goldin, MD4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 petrylak poster thumb

Click HERE to listen to an exclusive interview with Daniel Petrylak, MD, one of the authors of the study

1Yale Cancer Center, New Haven, CT USA
2Bayer HealthCare Pharmaceuticals, Inc., Whippany NJ, USA
3Bayer S.p.A., Milan, Italy
4UCLA Radiology Science, Los Angeles, CA USA

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland